[
  {
    "ts": "2025-07-14T11:00:00+00:00",
    "headline": "Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy",
    "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics® (NASDAQ: ABEO). Throughout clinical development, Simple Western enabled precise identification and quantification of Collagen VII, a complex therapeutic target critical to Z",
    "url": "https://finance.yahoo.com/news/bio-technes-simple-western-technology-110000320.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "8bcfa414-802c-3c81-8d79-3b4f87ff878e",
      "content": {
        "id": "8bcfa414-802c-3c81-8d79-3b4f87ff878e",
        "contentType": "STORY",
        "title": "Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy",
        "description": "",
        "summary": "Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics® (NASDAQ: ABEO). Throughout clinical development, Simple Western enabled precise identification and quantification of Collagen VII, a complex therapeutic target critical to Z",
        "pubDate": "2025-07-14T11:00:00Z",
        "displayTime": "2025-07-14T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c",
          "originalWidth": 400,
          "originalHeight": 146,
          "caption": "BT Logo (PRNewsfoto/Bio-Techne Corporation)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kJl8lfxgQq52fwY.Vvxfgw--~B/aD0xNDY7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c.cf.webp",
              "width": 400,
              "height": 146,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tkFsOYbYoGS0nXbE3BaqwA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f5bd457eba951c97e17e98b5c3c3878c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bio-technes-simple-western-technology-110000320.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bio-technes-simple-western-technology-110000320.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABEO"
            },
            {
              "symbol": "TECH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]